QR-Code

Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck

BackgroundImmune checkpoint inhibitors (ICIs) are essential in treating recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). However, the overall response rate (ORR) is limited to 10-20%, and subsequent chemotherapy is critical to maximizing the subjects’ prognosis.MethodsW...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Hideki Tanaka, Tomohiro Enokida, Susumu Okano, Takao Fujisawa, Nobukazu Tanaka, Naohiro Takeshita, Ryutaro Onaga, Yuta Hoshi, Akihisa Wada, Masanobu Sato, Yuri Ueda, Makoto Tahara
Format: Artigo
Sprache:Inglês
Veröffentlicht: Frontiers Media S.A. 2023-11-01
Schriftenreihe:Frontiers in Oncology
Schlagworte:
pembrolizumab
subsequent chemotherapy
paclitaxel
cetuximab
carboplatin
recurrent/metastasis squamous cell carcinoma of the head and neck
Online-Zugang:https://www.frontiersin.org/articles/10.3389/fonc.2023.1221352/full
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge